Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study.
Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Impact of Skeletal Muscle Radiodensity in Advanced Urothelial Carcinoma Undergoing Avelumab Maintenance Therapy.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMaintenance avelumab has shown improved overall survival compared to chemotherapy alone in first-line treatment of advanced urothelial carcinoma. This study evaluates real-world evidence of avelumab as first-line maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma (la/mUC). METHODS/PATIENTS: This was a multicenter, observational, retrospective and prospective study conducted in 22 Spanish centers. Patients were selected based on existing medical records of those treated with avelumab as first-line maintenance therapy before initiating the study (retrospective data), and those who continued to receive avelumab until the end of treatment or end of study (prospective data). Endpoints included median progression-free survival (mPFS), median overall survival (mOS) when available, PFS rate at 12 months (PFS12) and safety profile.
resultsOf the 125 patients enrolled, 113 were evaluable. The median follow-up of avelumab treatment was 10.7 months. Disease progression was the main reason for discontinuation in 70 (61.9%) patients, with a median time to progression disease of 6.8 months. The survival probability was 21.4% for mPFS, with progression disease or death in 67.3% of patients; 44.9% for PFS12, with progression disease or death in 52.2% of patients; and 92.2% for mOS, with death in 2.6% of patients. Adverse events (AEs) were reported in 12.4% of patients; 65.0% of AEs not related to avelumab, and 35.0% were serious (SAEs).
conclusionsThe real-world results support the effectiveness and manageable safety profile of avelumab as first-line in stage IV urothelial carcinoma. Further prospective studies with longer follow-up are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.